Inhibition of effector B cells by ibrutinib in systemic sclerosis
Open Access
- 30 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 22 (1), 1-8
- https://doi.org/10.1186/s13075-020-02153-8
Abstract
Systemic sclerosis (SSc) is a connective tissue disease with a significant morbidity and reduced survival of patients. Effective treatment and clinical control of the disease remain challenging. In particular, the development of pulmonary and cardiac fibrosis and pulmonary hypertension are severe complications responsible for excessive mortality. Currently available treatment strategies only alleviate symptoms and slow disease progression. Here, we investigated the therapeutic potential of ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor used in B cell malignancies, to alter B cell pathology in SSc in an in vitro model of autoimmunity. PBMCs and sorted B cells of 24 patients with SSc were used for functional testing after stimulation with hypomethylated DNA fragments (CpG) to induce an innate immune response. The effects of ibrutinib on cytokine production, autoantibody release, and activation of the transcription factor NFκB were evaluated. Ibrutinib was able to reduce the production of the profibrotic hallmark cytokines IL-6 and TNF-α mainly from the effector B cell population in patients with SSc. Importantly, small doses of ibrutinib (0.1 μM) preserved the production of immunoregulatory IL-10 while effectively inhibiting hyperactivated, profibrotic effector B cells. In a flow cytometry analysis of phosphorylated NFκB, an important transcription factor in the induction of innate immune responses in B cells, significantly less activation was observed with ibrutinib treatment. Our data could pave the avenue for a clinical application of ibrutinib for patients with SSc as a novel treatment option for the underlying pathogenetic immune imbalance contributing to disease onset and progression.Keywords
Funding Information
- Deutsche Krebshilfe (70112548)
- Clinician Scientist Program of the Faculty of Medicine Tuebingen (364-0-0, 390-0-0)
- Junior Research Group Grant of the Interdisciplinary Centre for Clinical Research (2383-0-0)
- Cancer Award of Wuerttemberg
- IZKF Postgraduate Program of the Faculty of Medicine Tuebingen (2019-1-18)
This publication has 37 references indexed in Scilit:
- Mechanisms of fibrosis: therapeutic translation for fibrotic diseaseNature Medicine, 2012
- BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-κB pathwayNature Communications, 2012
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences of the United States of America, 2010
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseAnnals Of The Rheumatic Diseases, 2010
- Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestationsArthritis Research & Therapy, 2009
- Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositisScandinavian Journal of Rheumatology, 2009
- Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine KinaseChemMedChem, 2006
- Toll-like receptors in systemic autoimmune diseaseNature Reviews Immunology, 2006
- Direct binding of anti–DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosisArthritis & Rheumatism, 2004
- PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signalingNature Immunology, 2002